With respect to small intestinal cancer, we hypothesized that the potential effect of SGLT2 inhibition might be partially related to SGLT1, an isoform of SGLT2 present in the intestine, liver, lung, brain, and salivary glands 48. Here, SLC5A2 is linked to small intestine cancer.